公开(公告)号：US20210403555A1

公开(公告)日：2021-12-30

申请号：US16626162

申请日：2019-06-14

Applicant: JAPANESE FOUNDATION FOR CANCER RESEARCH ,  API CO., LTD.

Inventor： Nobuhiko GYOBU ,  Naoya FUJITA ,  Mamoru KAKINO ,  Ai KAWASHIMA ,  Shinya FUJIHARA ,  Naoki GODA

IPC: C07K16/28 ,  C07K16/46

Abstract: The object of the present invention is to provide a humanized or mouse-human chimeric anti-podoplanin antibody or an antibody fragment containing the antigen-binding region thereof, and the object is achieved by providing an isolated humanized or mouse-human chimeric anti-podoplanin antibody which comprises a predetermined amino acid sequence, or an antibody fragment containing the antigen-binding region thereof.

公开(公告)号：US20190160066A1

公开(公告)日：2019-05-30

申请号：US16302207

申请日：2017-05-17

Applicant: JAPANESE FOUNDATION FOR CANCER RESEARCH

Inventor： Ryohei KATAYAMA ,  Ken UCHIBORI ,  Naoya FUJITA

IPC: A61K31/506 ,  A61K31/662 ,  G01N33/574 ,  A61P35/00

Abstract: A drug containing, as an active ingredient, a compound represented by ALK inhibitors such as brigatinib, AP26113-analog, and AZD3463 has been found to be effective against a non-small cell lung cancer having a point mutation at C797S in EGFR which has acquired a resistance to chemotherapy agents. Further, the drug used in combination with an anti-EGFR antibody demonstrates a notable suppression effect on the tumor growth. The drug has a potential to be a therapeutic agent effective against a non-small cell lung cancer which is resistant to gefitinib, a first generation therapeutic agent and osimertinib, a third generation therapeutic agent.